INEAS's Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia.

The Tunisian Health Technology Assessment (HTA) body, INEAS, conducted a cost-effectiveness analysis (CEA) of vemurafenib in the treatment of locally advanced or metastatic BRAF V600-mutated melanoma. The objective of this analysis was to enable the use of value-based pricing as a new approach to price negotiation. This study was part of a broader HTA report that was prepared in response to a joint request from the regulatory authorities and the CNAM, Tunisia's compulsory insurance scheme.

Disinfection booths in the context of COVID-19 pandemic.

Objectives: Industries have made claims on the effectiveness of a disinfection procedure in reducing COVID-19 transmission. This procedure is usually performed by automated dispersion of disinfectant on individuals when they go through a booth. This Health Technology Assessment (HTA) report is a systematic review that synthesizes the evidence on the efficacy and safety of using these booths and provides recommendations to the Ministry of Health to facilitate decision-making regarding the relevance of using this technology.

Rapid diagnostic tests : Pros, cons and potential use in the COVID-19 management in Tunisia.

Objectives: Diagnosis of SARS-CoV-2 infection is a major public health issue. In a context of limited diagnostic capacity with the reference technique (real-time RT-PCR), many manufacturers have developed rapid diagnostic tests (RDTs). Although very promising in theory, these tests have raised many questions.

Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics?

Background. Using Micral-test (MT) for screening microalbuminuria (MA) among type 2 diabetics (T2D) is helpful. We aimed at determining prevalence of MA and at describing the MT validity.